# Amgen, Inc. - Inspection Records

Source: https://www.keypedia.com/companies/amgen-inc/85ec512e-6991-42ee-9cd5-148cfe0ed3e8

> Inspection records and compliance data for Amgen, Inc. in Thousand Oaks, California. Access full analysis and detailed observations.

---

## Details

- Name: Amgen, Inc.
- FEI Number: 2026154
- City: Thousand Oaks
- State: California
- Country Name: United States
- Address Line 1: 1 Amgen Center Dr
- Zip Code: 91320

## Related Documents

- [483 - Amgen, Inc. - Unknown Date](https://www.keypedia.com/records/483/amgen-inc/a1384fcb-8ceb-4fff-b827-7aedea6283ba) — source: FDA, date: Invalid Date
- [483 - Amgen, Inc. - Unknown Date](https://www.keypedia.com/records/483/amgen-inc/0f69de0e-3c79-4e80-8482-84801428e3f1) — source: FDA, date: Invalid Date
- [483 - Amgen, Inc. - Unknown Date](https://www.keypedia.com/records/483/amgen-inc/3fd38f88-0f27-4242-95c6-59ba05cffdc8) — source: FDA, date: Invalid Date
- [CRL - Amgen, Inc. - Unknown Date](https://www.keypedia.com/records/crl/amgen-inc/b96aeb10-a857-41b8-8fa5-8ca2465cce5a) — source: FDA, date: Invalid Date
- [FDA Inspection 1278976 - Amgen, Inc. - 2025-08-07](https://www.keypedia.com/records/fda_inspections/amgen-inc/d97d8a62-a229-4000-9007-f563754eede5) — source: FDA, date: August 7, 2025
- [FDA Inspection 1278976 - Amgen, Inc. - 2025-08-07](https://www.keypedia.com/records/fda_inspections/amgen-inc/41a4234d-3f2f-4bab-ab8b-9a1e17008055) — classification: No Action Indicated (NAI), source: FDA, date: August 7, 2025
- [483 - Amgen, Inc. - 2025-03-13](https://www.keypedia.com/records/483/amgen-inc/f158a248-7fa2-44df-9ef9-74b5f972894b) — source: FDA, date: March 13, 2025
- [FDA Inspection 1256132 - Amgen, Inc. - 2025-03-13](https://www.keypedia.com/records/fda_inspections/amgen-inc/8601b5a4-a27d-4f90-9399-1e0398db8be7) — classification: Voluntary Action Indicated (VAI), source: FDA, date: March 13, 2025
- [483 - Amgen, Inc. - 2024-02-06](https://www.keypedia.com/records/483/amgen-inc/e9edaa4a-6d46-4674-882b-fc862d99421c) — source: FDA, date: February 6, 2024
- [FDA Inspection 1240449 - Amgen, Inc. - 2024-02-06](https://www.keypedia.com/records/fda_inspections/amgen-inc/fe67a98f-c816-4387-bbd9-9d30c82ae96a) — source: FDA, date: February 6, 2024
- [FDA Inspection 1220409 - Amgen, Inc. - 2023-09-14](https://www.keypedia.com/records/fda_inspections/amgen-inc/78815a66-7fde-4e3c-b744-48f87db72016) — classification: No Action Indicated (NAI), source: FDA, date: September 14, 2023
- [483 - Amgen, Inc. - 2019-12-13](https://www.keypedia.com/records/483/amgen-inc/38972f72-b21d-41b2-bb8b-25e715f425e9) — source: FDA, date: December 13, 2019
- [EIR - Amgen, Inc. - 2019-12-13](https://www.keypedia.com/records/eir/amgen-inc/7155ec06-4efb-4490-8b2d-eecd030871d1) — source: FDA, date: December 13, 2019
- [FDA Inspection 1112791 - Amgen, Inc. - 2019-12-13](https://www.keypedia.com/records/fda_inspections/amgen-inc/f7c02d35-9f41-4022-9b49-996bf75204ed) — classification: Voluntary Action Indicated (VAI), source: FDA, date: December 13, 2019
- [FDA Inspection 1028320 - Amgen, Inc. - 2017-08-21](https://www.keypedia.com/records/fda_inspections/amgen-inc/e1905cc5-73ce-4b78-91c5-b5621663675b) — classification: No Action Indicated (NAI), source: FDA, date: August 21, 2017
- [483 - Amgen, Inc. - 2017-05-16](https://www.keypedia.com/records/483/amgen-inc/a23066f5-45d7-4383-9490-ac82f211990c) — source: FDA, date: May 16, 2017
- [FDA Inspection 1014825 - Amgen, Inc. - 2017-04-19](https://www.keypedia.com/records/fda_inspections/amgen-inc/1623f72b-121b-4bed-b0fa-6ddf83e70f7a) — classification: No Action Indicated (NAI), source: FDA, date: April 19, 2017
- [FDA Inspection 1014808 - Amgen, Inc. - 2017-04-19](https://www.keypedia.com/records/fda_inspections/amgen-inc/07317c73-f6bc-4986-a1e3-67eb147496c1) — classification: No Action Indicated (NAI), source: FDA, date: April 19, 2017
- [FDA Inspection 1008341 - Amgen, Inc. - 2017-03-17](https://www.keypedia.com/records/fda_inspections/amgen-inc/89a303a8-e43d-46f4-b05e-110ccdd0b68d) — classification: No Action Indicated (NAI), source: FDA, date: March 17, 2017
- [WARNING_LETTER - Amgen, Inc. - 2013-06-17](https://www.keypedia.com/records/warning_letter/amgen-inc/980f4f23-54ec-4bfd-b859-cf7b7d38566c) — source: FDA, date: June 17, 2013

## Related Companies

- [Merck Sharp & Dohme LLC](https://www.keypedia.com/companies/merck-sharp-dohme-llc/842c6e25-ee89-453c-a5b0-6b039c187744)
- [AgroChem USA, LLC](https://www.keypedia.com/companies/agrochem-usa-llc/007b3455-bf3c-4d23-b1e7-0be79ebba21e)
- [Advanced Accelerator Applications (Italy) srl](https://www.keypedia.com/companies/advanced-accelerator-applications-italy-srl/09ac059c-6735-4082-8674-a88476dbdbc6)
- [OMRIX Biopharmaceuticals LTD](https://www.keypedia.com/companies/omrix-biopharmaceuticals-ltd/bf1b8f1e-b1c7-47be-bb38-f85e1cff944d)
- [Aprecia Pharmaceuticals LLC](https://www.keypedia.com/companies/aprecia-pharmaceuticals-llc/126049a3-6c3d-4616-8d44-006827a308c3)
- [Changzhou Pharmaceutical Factory](https://www.keypedia.com/companies/changzhou-pharmaceutical-factory/eea165e1-3df2-47c8-94b9-e8400af46bc4)
- [Gland Pharma Limited](https://www.keypedia.com/companies/gland-pharma-limited/9d02bb1e-32f9-45c5-9b90-f52622553c63)
- [Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany](https://www.keypedia.com/companies/halo-pharmaceutical-inc-dba-cambrex-whippany/1464443d-ae5a-4d06-959c-d1ccb1b213a2)
- [Vericel Corporation](https://www.keypedia.com/companies/vericel-corporation/1955c523-5115-491b-a705-2c526deb9ff6)
- [Norbrook Laboratories Limited](https://www.keypedia.com/companies/norbrook-laboratories-limited/c9294f28-e127-43a0-b824-82a6f41fabfd)

## Related Officers

- [Investigator](https://www.keypedia.com/people/roger-f-zabinski/87e05838-f8b5-489a-8db7-6669e68a2c2e)
- [Esther C. Broner](https://www.keypedia.com/people/esther-c-broner/5df7ca72-a21f-4586-a5e0-8a782045281c)
- [Zhong Li](https://www.keypedia.com/people/zhong-li/18545b20-7fa5-4850-9dd4-cffb40c41f8d)
- [Marc Kubasak, PhD](https://www.keypedia.com/people/marc-kubasak-phd/0022703d-5fa9-4022-9d76-821be46e8f5d)